Comorbidities and polypharmacy among HIV-positive patients aged 50 years and over: a case–control study
Abstract Objective This study was to determine and compare the prevalences of polypharmacy and comorbidities in patients aged 50 years or older with those patients younger than 50 years in a Mexican population. Results One hundred and twenty-five patients were enrolled, 60 (48%) were aged 50 years o...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-09-01
|
Series: | BMC Research Notes |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13104-019-4576-6 |
id |
doaj-3a84bc1e9e3e4735949a9157683dbc96 |
---|---|
record_format |
Article |
spelling |
doaj-3a84bc1e9e3e4735949a9157683dbc962020-11-25T03:44:59ZengBMCBMC Research Notes1756-05002019-09-011211610.1186/s13104-019-4576-6Comorbidities and polypharmacy among HIV-positive patients aged 50 years and over: a case–control studyJosé Antonio Mata-Marín0Moisés Hermilo Martínez-Osio1Carla I. Arroyo-Anduiza2María de los Ángeles Berrospe-Silva3Alberto Chaparro-Sánchez4Itzel Cruz-Grajales5Javier Enrique Cruz-Herrera6Luis Antonio Uribe-Noguez7Jesus E. Gaytán-Martínez8Medardo Jerónimo-Morales9Infectious Diseases Department, Instituto Mexicano del Seguro Social, Hospital de Infectología, “La Raza” National Medical Center, IMSSInternal Medicine Department, Hospital General, “La Raza” National Medical Center, IMSSClinical Pathology Department, Banco Central de Sangre, Hospital de Especialidades, “La Raza” National Medical Center, IMSSInfectious Diseases Department, Instituto Mexicano del Seguro Social, Unidad de Infectología “Juan I. Menchaca”, Ext HGR 45, IMSSInfectious Diseases Department, Instituto Mexicano del Seguro Social, Hospital de Infectología, “La Raza” National Medical Center, IMSSInternal Medicine Department, Hospital General, “La Raza” National Medical Center, IMSSInternal Medicine Department, Hospital HGZ-# 3Infectious Diseases Department, Instituto Mexicano del Seguro Social, Hospital de Infectología, “La Raza” National Medical Center, IMSSInfectious Diseases Department, Instituto Mexicano del Seguro Social, Hospital de Infectología, “La Raza” National Medical Center, IMSSInternal Medicine Department, Hospital General, “La Raza” National Medical Center, IMSSAbstract Objective This study was to determine and compare the prevalences of polypharmacy and comorbidities in patients aged 50 years or older with those patients younger than 50 years in a Mexican population. Results One hundred and twenty-five patients were enrolled, 60 (48%) were aged 50 years or older. The median CD4+ cell counts were 509 cells/μL (interquartile range [IQR]: 324–730) for the older patients and 384 cells/μL (IQR: 262–562) (P = 0.021) for the younger patients. Viral suppression were significantly higher in the older group: 80% vs. 63% (P = 0.037). The number of comorbidities was significantly higher in the older group, with a median of 2 (IQR: 2–3) vs. 1 (IQR: 0–1) (P ≤ 0.001). After adjustment of the logistic regression model in the older group, the following comorbidities differed between the age groups: systemic arterial hypertension (odds ratio [OR]: 15.75; 95% confidence interval [CI] 3.49–71.05; P = < 0.001), diabetes mellitus (OR: 14.36; 95% CI 1.79–115.07; P = 0.001), osteoarthritis (OR: 10.33; 95% CI 2.88–37.05; P = < 0.001), hyperlipidemia (OR: 2.78; 95% CI 1.22–6.34; P = 0.001), and polypharmacy (OR: 6.58; 95% CI 3.01–14.39; P = 0.001).http://link.springer.com/article/10.1186/s13104-019-4576-6ComorbidityHIVPolypharmacy |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
José Antonio Mata-Marín Moisés Hermilo Martínez-Osio Carla I. Arroyo-Anduiza María de los Ángeles Berrospe-Silva Alberto Chaparro-Sánchez Itzel Cruz-Grajales Javier Enrique Cruz-Herrera Luis Antonio Uribe-Noguez Jesus E. Gaytán-Martínez Medardo Jerónimo-Morales |
spellingShingle |
José Antonio Mata-Marín Moisés Hermilo Martínez-Osio Carla I. Arroyo-Anduiza María de los Ángeles Berrospe-Silva Alberto Chaparro-Sánchez Itzel Cruz-Grajales Javier Enrique Cruz-Herrera Luis Antonio Uribe-Noguez Jesus E. Gaytán-Martínez Medardo Jerónimo-Morales Comorbidities and polypharmacy among HIV-positive patients aged 50 years and over: a case–control study BMC Research Notes Comorbidity HIV Polypharmacy |
author_facet |
José Antonio Mata-Marín Moisés Hermilo Martínez-Osio Carla I. Arroyo-Anduiza María de los Ángeles Berrospe-Silva Alberto Chaparro-Sánchez Itzel Cruz-Grajales Javier Enrique Cruz-Herrera Luis Antonio Uribe-Noguez Jesus E. Gaytán-Martínez Medardo Jerónimo-Morales |
author_sort |
José Antonio Mata-Marín |
title |
Comorbidities and polypharmacy among HIV-positive patients aged 50 years and over: a case–control study |
title_short |
Comorbidities and polypharmacy among HIV-positive patients aged 50 years and over: a case–control study |
title_full |
Comorbidities and polypharmacy among HIV-positive patients aged 50 years and over: a case–control study |
title_fullStr |
Comorbidities and polypharmacy among HIV-positive patients aged 50 years and over: a case–control study |
title_full_unstemmed |
Comorbidities and polypharmacy among HIV-positive patients aged 50 years and over: a case–control study |
title_sort |
comorbidities and polypharmacy among hiv-positive patients aged 50 years and over: a case–control study |
publisher |
BMC |
series |
BMC Research Notes |
issn |
1756-0500 |
publishDate |
2019-09-01 |
description |
Abstract Objective This study was to determine and compare the prevalences of polypharmacy and comorbidities in patients aged 50 years or older with those patients younger than 50 years in a Mexican population. Results One hundred and twenty-five patients were enrolled, 60 (48%) were aged 50 years or older. The median CD4+ cell counts were 509 cells/μL (interquartile range [IQR]: 324–730) for the older patients and 384 cells/μL (IQR: 262–562) (P = 0.021) for the younger patients. Viral suppression were significantly higher in the older group: 80% vs. 63% (P = 0.037). The number of comorbidities was significantly higher in the older group, with a median of 2 (IQR: 2–3) vs. 1 (IQR: 0–1) (P ≤ 0.001). After adjustment of the logistic regression model in the older group, the following comorbidities differed between the age groups: systemic arterial hypertension (odds ratio [OR]: 15.75; 95% confidence interval [CI] 3.49–71.05; P = < 0.001), diabetes mellitus (OR: 14.36; 95% CI 1.79–115.07; P = 0.001), osteoarthritis (OR: 10.33; 95% CI 2.88–37.05; P = < 0.001), hyperlipidemia (OR: 2.78; 95% CI 1.22–6.34; P = 0.001), and polypharmacy (OR: 6.58; 95% CI 3.01–14.39; P = 0.001). |
topic |
Comorbidity HIV Polypharmacy |
url |
http://link.springer.com/article/10.1186/s13104-019-4576-6 |
work_keys_str_mv |
AT joseantoniomatamarin comorbiditiesandpolypharmacyamonghivpositivepatientsaged50yearsandoveracasecontrolstudy AT moiseshermilomartinezosio comorbiditiesandpolypharmacyamonghivpositivepatientsaged50yearsandoveracasecontrolstudy AT carlaiarroyoanduiza comorbiditiesandpolypharmacyamonghivpositivepatientsaged50yearsandoveracasecontrolstudy AT mariadelosangelesberrospesilva comorbiditiesandpolypharmacyamonghivpositivepatientsaged50yearsandoveracasecontrolstudy AT albertochaparrosanchez comorbiditiesandpolypharmacyamonghivpositivepatientsaged50yearsandoveracasecontrolstudy AT itzelcruzgrajales comorbiditiesandpolypharmacyamonghivpositivepatientsaged50yearsandoveracasecontrolstudy AT javierenriquecruzherrera comorbiditiesandpolypharmacyamonghivpositivepatientsaged50yearsandoveracasecontrolstudy AT luisantoniouribenoguez comorbiditiesandpolypharmacyamonghivpositivepatientsaged50yearsandoveracasecontrolstudy AT jesusegaytanmartinez comorbiditiesandpolypharmacyamonghivpositivepatientsaged50yearsandoveracasecontrolstudy AT medardojeronimomorales comorbiditiesandpolypharmacyamonghivpositivepatientsaged50yearsandoveracasecontrolstudy |
_version_ |
1724512275840106496 |